Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen
What the buyer wrote
NHS Arden and Greater East Midlands CSU (AGCSU) on behalf of NHS England Specialised Commissioning is inviting suitably qualified and experienced providers to deliver Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen under the Compliance Process specified in Document 1 - Process Overview of process documentation. On 24 July 2019, NICE published Technology appraisal guidance on the use of the drug Nusinersen to treat patients with 5q Spinal Muscular Atrophy (SMA). This is a rare, genetic, neuromuscular disease, characterised by spinal motor neuron loss, muscle atrophy and motor impairment. SMA is debilitating for all patients and fatal for the w…
Details
- What the buyer calls it
- Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen
- How they are buying
- The buyer did not say
- Type
- services
- Work starts
- 2 Jan 2020
- Work ends
- 1 Jan 2023
- Kind of work
- Mental health and wellbeing services
Who the buyer named
Sarah Protheroe was the named contact on this notice.